Patents by Inventor Kristian Pietras
Kristian Pietras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230310385Abstract: Disclosed is that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype, by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the present disclosure finds that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.Type: ApplicationFiled: March 14, 2023Publication date: October 5, 2023Inventors: Ulf Eriksson, Kristian Pietras, Pernilla Roswall
-
Patent number: 11633382Abstract: The invention discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the invention discloses that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.Type: GrantFiled: November 10, 2016Date of Patent: April 25, 2023Assignee: Paracrine Therapeutics ABInventors: Ulf Eriksson, Kristian Pietras, Pernilla Roswall
-
Publication number: 20220017600Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: February 25, 2021Publication date: January 20, 2022Applicants: Acceleron Pharma Inc., Ludwig Institute for Cancer Research Ltd.Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
-
Publication number: 20210388104Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: January 4, 2021Publication date: December 16, 2021Applicants: Ludwig Institute for Cancer Research Ltd., Acceleron Pharma, Inc.Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
-
Publication number: 20210186932Abstract: The invention discloses that ER-negative breast cancers can be converted into ER positive breast cancers, such as to a breast cancer of luminal-like phenotype by treatment with anti-PDGF-CC antibodies. ER-positive breast cancers, including luminal-like breast cancers can be treated with anti-estrogen treatment. On this basis the invention discloses that surprisingly, ER-negative breast cancers can be treated with anti-estrogen treatment, if the treatment is combined with treatment with anti-PDGF-CC antibodies. Said treatment may for example be an adjuvant treatment, for example a treatment aiming at reducing the risk of relapse of a breast cancer after removal of the primary tumor by surgery.Type: ApplicationFiled: November 10, 2016Publication date: June 24, 2021Applicant: Paracrine Therapeutics ABInventors: Ulf Eriksson, Kristian Pietras, Pernilla Roswall
-
Publication number: 20190048063Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: July 30, 2018Publication date: February 14, 2019Applicants: Acceleron Pharma Inc., Ludwig Institute for Cancer Research Ltd.Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
-
Patent number: 10059756Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: GrantFiled: April 13, 2012Date of Patent: August 28, 2018Assignee: Acceleron Pharma Inc.Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
-
Publication number: 20180179293Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: February 13, 2018Publication date: June 28, 2018Applicants: Ludwig Institute for Cancer Research Ltd., Acceleron Pharma, Inc.Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
-
Publication number: 20130040896Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: April 13, 2012Publication date: February 14, 2013Applicant: ACCELERON PHARMA, INC.Inventors: ASYA GRINBERG, JOHN KNOPF, RAVINDRA KUMAR, ROBERT S. PEARSALL, JASBIR SEEHRA, KRISTIAN PIETRAS
-
Publication number: 20130039910Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: April 13, 2012Publication date: February 14, 2013Applicant: ACCELERON PHARMA, INC.Inventors: ASYA GRINBERG, JOHN KNOPF, RAVINDRA KUMAR, ROBERT S. PEARSALL, JASBIR SEEHRA, KRISTIAN PIETRAS
-
Patent number: 8158584Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: GrantFiled: May 1, 2009Date of Patent: April 17, 2012Assignees: Acceleron Pharma, Inc., Ludwig Institute for Cancer Research Ltd.Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Robert S. Pearsall, Jasbir Seehra, Kristian Pietras
-
Patent number: 7723339Abstract: The present invention relates to a combination comprising N-{5-[4-(4-methyl-piperazino-methyl) -benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and an epothiione derivative; pharmaceutical composition comprising said combination; method of treatment comprising said combination; and commercial packages comprising said combination.Type: GrantFiled: February 26, 2002Date of Patent: May 25, 2010Assignee: Novartis AGInventors: Ralf Brandt, Elisabeth Buchdunger, Carl-Henrik Heldin, Arne Östman, Kristian Pietras, Terence O'Reilly, John D Rothermel, Peter Traxler, Markus Wartmann
-
Publication number: 20090311272Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: May 1, 2009Publication date: December 17, 2009Inventors: Asya Grinberg, John Knopf, Ravindra Kumar, Robert S. Pearsall, Jasbir Seehra, Kristian Pietras
-
Publication number: 20070037825Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used for enhancing the effect of radioimmunotherapy of tumors.Type: ApplicationFiled: July 17, 2003Publication date: February 15, 2007Inventors: Janina Baranowska-Kortylewicz, Takashi Kurizaki, Michio Abe, Arne Ostman, Kristian Pietras
-
Publication number: 20070021327Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.Type: ApplicationFiled: September 8, 2006Publication date: January 25, 2007Applicant: GILEAD SCIENCES, INC.Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin
-
Patent number: 7141375Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.Type: GrantFiled: March 2, 2004Date of Patent: November 28, 2006Assignee: Gilead Sciences, Inc.Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin
-
Publication number: 20040224335Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.Type: ApplicationFiled: March 2, 2004Publication date: November 11, 2004Applicant: Gilead Sciences, Inc.Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin
-
Publication number: 20040132754Abstract: The invention relates to a combination which comprises (a) a signal transduction inhibitor selected from a PDGF (platelet-derived growth factor) receptor tyrosine kinase inhibitor and an active ingredient which decreases the activity of the epidermal growth factor (EGF) an epothilone derivative of formula (I) in which compound A represents O or NRn, wherein Rn is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the delay of progression or treatment of a proliferative disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease; a commercial package comprising such a combination as a combined preparation; and to a method of treatment of a warm-blooded animal.Type: ApplicationFiled: February 18, 2004Publication date: July 8, 2004Inventors: Ralf Brandt, Elisabeth Buchdunger, Carl-Henrik Heldin, Arne Ostman, Kristian Pietras, Terence O'Reilly, John David Rothermel, Peter Traxler, Markus Wartmann
-
Patent number: 6699843Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.Type: GrantFiled: May 17, 2001Date of Patent: March 2, 2004Assignee: Gilead Sciences, Inc.Inventors: Kristian Pietras, Arne Östman, Carl-Henrik Heldin, Kristofer Rubin
-
Publication number: 20020034506Abstract: A method is provided for treating solid tumors comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent. In a preferred embodiment the PDGF aptamer is identified using the SELEX process for the Systematic Evolution of Ligands by Exponential enrichment. A method is also provided for reducing the interstitial fluid pressure (IFP) of a solid tumor comprising administering a PDGF aptamer. Finally, a method is provided for increasing the uptake of cytotoxic agents into a tumor comprising administering a composition comprising a PDGF aptamer and a cytotoxic agent.Type: ApplicationFiled: May 17, 2001Publication date: March 21, 2002Applicant: Gilead Sciences, Inc.Inventors: Kristian Pietras, Arne Ostman, Carl-Henrik Heldin, Kristofer Rubin